2024-09-28 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison**

Pfizer Inc. (PFE) is a global pharmaceutical company, known for its wide range of prescription drugs and vaccines.  

As of the latest data, PFE has accumulated a total return of -12.21%, significantly underperforming the S&P 500 (VOO) which has a total return of 134.22%. This represents a significant gap of -146.43% relative to the benchmark. 

**2. Recent Price Action**

The current closing price of PFE is $28.97. The stock is currently trading below its 5-day, 20-day and 60-day moving averages, indicating a potential downtrend. 

* 5-day moving average: $29.2
* 20-day moving average: $29.2
* 60-day moving average: $29.21

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 55.1 - The RSI is slightly above the neutral level of 50, suggesting the stock is in a neutral to slightly bullish territory. 
* **PPO (Percentage Price Oscillator):** -0.16 -  The PPO is negative, indicating a potential downtrend.
* **Delta_Previous_Relative_Divergence:** -3.32 - The negative value suggests a recent downward shift in the stock's relative strength. 
* **Expected Return:** 0.0% - This indicates a maximum of 5-year expected return is 0% based on the current investment amount. 

**4. Earnings Analysis**

Pfizer's recent earnings have been mixed. The company has consistently beaten earnings expectations, but overall, the trend is somewhat concerning. 

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

The latest earnings report for the quarter ending July 30, 2024, showed EPS of 0.6, exceeding the expected EPS of 0.458. However, the overall trend suggests a potential decline in earnings. 

**5. News and Recent Issues**

* **Recent Market Outlook for PFE:** The market outlook for Pfizer is mixed. Analysts are still debating the impact of the company's reliance on COVID-19 vaccines and treatments. 
* **Analyst Opinions and Performance Highlights:** According to FINBOLD, the average target price for PFE is $40.10, indicating a potential upside. However, analysts have also expressed concerns about the company's long-term growth prospects.

**6.  Overall Analysis**

Pfizer has significantly underperformed the market, and the recent technical indicators point to a potential downtrend. However, the company has consistently beaten earnings expectations, which may provide some support for the stock. Investors should closely monitor the company's performance and any news regarding the potential impact of its reliance on COVID-19 products.

**7. Recommendations**

* **Buy:**  If you believe in the long-term growth potential of Pfizer and are comfortable with the risks associated with its reliance on COVID-19 products,  a buy position could be considered.
* **Hold:** If you are uncertain about the company's future prospects, a hold position might be a safer option. 
* **Sell:** If you are concerned about the company's long-term prospects and the potential for further underperformance, a sell position might be advisable. 

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. Always conduct thorough research and consult with a qualified financial advisor before making any investment decisions. 
